サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536216

進行性核上性麻痺治療の世界市場

Progressive Supranuclear Palsy Treatment

出版日
ページ情報
英文 134 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
進行性核上性麻痺治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 134 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

進行性核上性麻痺治療の世界市場は2030年までに1,910万米ドルに達する見込み

2023年に1,360万米ドルと推定される進行性核上性麻痺治療の世界市場は、分析期間2023-2030年にCAGR 5.0%で成長し、2030年には1,910万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである薬物療法は、CAGR 6.1％を記録し、分析期間終了時には870万米ドルに達すると予測されます。理学療法分野の成長率は、分析期間中CAGR 4.7％と推定されます。

米国市場は360万米ドルと推定、中国はCAGR4.7%で成長予測

米国の進行性核上性麻痺治療市場は2023年に360万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 4.7%で成長し、2030年には300万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.6％と4.0％と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

主要動向と促進要因

進行性核上性麻痺（PSP）はまれな神経変性疾患で、運動、歩行（歩行）と平衡の制御、言語、嚥下、視覚、気分と行動、認知能力に影響を及ぼします。脳の特定の領域、主に体の動きや認知機能を司る領域の脳細胞の劣化によって生じる。最も特徴的な症状は、歩行時のバランスの崩れや、眼球運動、特に上や下を見ることの困難さです。これらの症状は徐々に悪化し、嚥下障害によって肺炎などの生命を脅かす合併症を引き起こすことも少なくないです。現在のところ、PSPを治療する方法はなく、生活の質を向上させるために症状を管理することが治療の中心となっています。この管理には、症状を軽減するための薬物療法、運動能力を高め転倒を予防するための理学療法、コミュニケーションの課題に対処するための言語療法などが含まれます。

PSP治療の研究開発は現在も進行中であり、いくつかの革新的なアプローチが研究されています。薬理学的研究は主に、病気の進行を遅らせたり、症状を緩和したりすることを目的とした神経保護薬や疾患修飾薬に焦点を当てています。その中で最も有望なのはタウ蛋白凝集阻害剤です。タウの異常蓄積はPSPの特徴です。脳深部刺激療法や神経外科的治療など、非薬理学的治療も検討されているが、これらはまだ研究の初期段階です。PSPの症状が複雑であることから、神経内科医、理学療法士、言語療法士、作業療法士が参加する集学的治療がますます採用されるようになってきており、患者が経験する幅広い症状に対応するように設計されています。

進行性核上性麻痺市場の成長は、世界の高齢化に伴う神経変性疾患の有病率の増加、より効果的な治療に対する需要の高まりなど、いくつかの要因によって牽引されています。また、診断技術の進歩も大きく寄与しており、PSPのより早期かつ正確な診断が可能になったことで、治療の対象となる患者数が増加しています。バイオテクノロジー企業や製薬企業による、PSPの治療法やより効果的な治療法の発見を目指した研究開発への投資が増加していることも、主な促進要因の一つです。希少疾患に対する認識やアドボカシーの高まりは、税制優遇措置、助成金、新規治療法の早期承認などのインセンティブを含む、規制当局の支援環境も育んでいます。さらに、患者擁護運動の高まりは、オーダーメイドのヘルスケアソリューションの必要性を強調し、市場の需要と現在進行中の臨床研究の焦点の両方に影響を与えています。これらの要因が相まって、治療アプローチの進歩とPSP市場の開拓が促進され、患者の予後改善と治療の可能性の拡大が期待されます。

調査対象企業の例（全86件）

  • AbbVie, Inc.
  • AC Immune SA
  • Alzprotect
  • Amylyx Pharmaceuticals
  • Asahi Kasei Pharma Corporation
  • Asceneuron
  • Biogen, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Oncolys BioPharma
  • Retrotope
  • TauRx Pharmaceuticals Ltd.
  • Transposon Therapeutics, Inc.
  • UCB SA
  • Woolsey Pharmaceuticals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP26820

Global Progressive Supranuclear Palsy Treatment Market to Reach US$19.1 Million by 2030

The global market for Progressive Supranuclear Palsy Treatment estimated at US$13.6 Million in the year 2023, is expected to reach US$19.1 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Pharmacological Therapy, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$8.7 Million by the end of the analysis period. Growth in the Physical Therapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Million While China is Forecast to Grow at 4.7% CAGR

The Progressive Supranuclear Palsy Treatment market in the U.S. is estimated at US$3.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Key Trends and Drivers

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and cognitive abilities. It arises due to the deterioration of brain cells in specific areas of the brain, primarily those that control the body's movements and cognitive functions. The most distinctive symptom, which often results in early misdiagnosis, involves a loss of balance while walking and difficulty managing eye movements, specifically in looking up and down. These symptoms progressively worsen, often leading to life-threatening complications such as pneumonia, due to swallowing difficulties. Currently, there is no cure for PSP, and treatments focus on managing symptoms to improve quality of life. This management can involve medication to reduce symptoms, physical therapy to enhance mobility and prevent falls, and speech therapy to address communication challenges.

Research and development within the field of PSP treatment are ongoing, with several innovative approaches under investigation. Pharmacological research primarily focuses on neuroprotective and disease-modifying drugs that aim to slow the progression of the disease or alleviate its symptoms. Most promising among these are tau protein aggregation inhibitors, as abnormal accumulation of tau is a hallmark of PSP. Non-pharmacological interventions are also being explored, such as deep brain stimulation and other neurosurgical options, though these are still in the early stages of research. Given the complexity of PSP symptoms, multidisciplinary care approaches are increasingly adopted, involving neurologists, physical therapists, speech therapists, and occupational therapists, designed to address the broad spectrum of symptoms experienced by patients.

The growth in the Progressive Supranuclear Palsy market is driven by several factors, including the increasing prevalence of neurodegenerative disorders with aging populations globally, which heightens the demand for more effective treatments. Advances in diagnostic technologies have also significantly contributed, allowing for earlier and more accurate diagnosis of PSP, thereby increasing the number of individuals eligible for treatment. Another key driver is the rising investment in research and development by biotech and pharmaceutical companies aimed at finding a cure or more effective management options for PSP. Enhanced awareness and advocacy for rare disorders have also fostered a supportive regulatory environment that often includes incentives like tax breaks, funding grants, and fast-track approvals for novel therapies. Furthermore, growing patient advocacy movements are emphasizing the need for tailored healthcare solutions, influencing both market demand and the focus of ongoing clinical research. These factors collectively stimulate advancements in treatment approaches and the development of the PSP market, promising improved patient outcomes and expanded therapeutic possibilities.

Select Competitors (Total 86 Featured) -

  • AbbVie, Inc.
  • AC Immune SA
  • Alzprotect
  • Amylyx Pharmaceuticals
  • Asahi Kasei Pharma Corporation
  • Asceneuron
  • Biogen, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Oncolys BioPharma
  • Retrotope
  • TauRx Pharmaceuticals Ltd.
  • Transposon Therapeutics, Inc.
  • UCB SA
  • Woolsey Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Progressive Supranuclear Palsy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Awareness and Diagnosis Rates of Progressive Supranuclear Palsy
    • Advances in Neuroimaging Technologies Enhancing Diagnostic Accuracy
    • Emerging Biomarkers for Early and Accurate Diagnosis
    • Development of Disease-Modifying Therapies
    • Impact of Genetic Research on Treatment Approaches
    • Increased Funding for Rare Neurodegenerative Disorders
    • Government Initiatives Supporting Neurological Research
    • Expansion of Targeted Therapy and Personalized Medicine
    • Innovations in Drug Delivery Systems
    • Integration of AI and Machine Learning in Drug Development
    • Challenges in Clinical Trial Recruitment
    • Global Health Aging Populations Increasing Prevalence
    • Neuroprotective Treatment Approaches Gaining Traction
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Progressive Supranuclear Palsy Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Physical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Speech Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Symptomatic Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • JAPAN
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • CHINA
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • EUROPE
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • FRANCE
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • GERMANY
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030

IV. COMPETITION